<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CHORIONIC GONADOTROPIN</span><br/>(go-nad'oh-troe-pin)<br/><span class="topboxtradename">Antuitrin, </span><span class="topboxtradename">A.P.L., </span><span class="topboxtradename">Chorex, </span><span class="topboxtradename">Chorigon, </span><span class="topboxtradename">Choron 10, </span><span class="topboxtradename">Corgonject-5, </span><span class="topboxtradename">Follutein, </span><span class="topboxtradename">Glukor, </span><span class="topboxtradename">Gonic, </span><span class="topboxtradename">HCG, </span><span class="topboxtradename">Pregnyl, </span><span class="topboxtradename">Profasi HP<br/></span><b>Classifications:</b> <span class="classification">hormone &amp; synthetic substitute</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5,000 units, 10,000 units, 20,000 units vials</p>
<h1><a name="action">Actions</a></h1>
<p>Human chorionic gonadotropin (HCG) is a polypeptide hormone produced by the placenta and extracted from urine during first
         trimester of pregnancy. Actions nearly identical to those of pituitary luteinizing hormone (LH). Promotes production of gonadal
         steroid hormones by stimulating interstitial cells of the testes to produce androgen, and the corpus luteum of the ovary to
         produce progesterone.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Administration of HCG to women of childbearing age with normal functioning ovaries causes maturation of the ovarian follicle
         and triggers ovulation. When given during normal pregnancy, it maintains corpus luteum after LH decreases, supports continuing
         secretion of estrogen and progesterone, and prevents ovulation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prepubertal cryptorchidism not due to anatomic obstruction and male hypogonadism secondary to pituitary deficiency. Also used
         in conjunction with menotropins to induce ovulation and pregnancy in infertile women in whom the cause of anovulation is secondary;
         ovulation usually occurs within 18 h. To stimulate spermatogenesis in males with hypogonadism.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Corpus luteum dysfunction.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to HCG, hypogonadism of testicular origin, hypertrophy or tumor of pituitary, prostatic carcinoma or
         other androgen-dependent neoplasms, precocious puberty; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Epilepsy, migraine, asthma, cardiac or renal disease; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prepubertal Cryptorchidism</span><br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> 4000 units 3 times/wk for 3 wk, <i>or</i> 5000 units q.o.d. for 4 doses, <i>or</i> 5001000 units 3 times/wk for 46 wk<br/><br/><span class="indicationtitle">Hypogonadotropic Hypogonadism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 5001000 units 3 times/wk for 3 wk, then 2 times/wk for 3 wk <i>or</i> 4000 units 3 times/wk for 69 mo followed by 2000 units 3 times/wk for 3 mo<br/><br/><span class="indicationtitle">Stimulation of Spermatogenesis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 5000 units 3 times/wk until normal testosterone levels are achieved (46 mo), then 2000 units 2 times/wk with menotropins
               for 4 mo<br/><br/><span class="indicationtitle">Induction of Ovulation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 5001000 units 1 d following last dose of menotropins<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Reconstitute only with diluent supplied by manufacturer.</li>
<li>Following reconstitution solution is stable for 3090 d, depending on manufacturer, when refrigerated; thereafter potency
            decreases.
         </li>
<li>Store powder for injection at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Edema, pain at injection site, <span class="speceff-life">arterial thromboembolism</span>. <span class="typehead">Endocrine:</span> Gynecomastia, precocious puberty, increased urinary steroid excretion, ectopic pregnancy (incidence low). When used with menotropins
      (human menopausal gonadotropin): Ovarian hyperstimulation (ascites with or without pain, pleural effusion, ruptured ovarian
      cysts with resultant hemoperitoneum, multiple births). <span class="typehead">CNS:</span> Headache, irritability, restlessness, depression, fatigue. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="alt">Pregnancy tests:</span> possibility of false results.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant drug interactions established. <span class="typehead">Herbal:</span>
<b>Black cohosh</b> may antagonize fertility effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 2 h. <span class="typehead">Peak:</span> 6 h. <span class="typehead">Distribution:</span> Testes in males, ovaries in females. <span class="typehead">Elimination:</span> 1012% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess prepubescent males for development of secondary sex characteristics.</li>
<li>Assess females for and report excessive menstrual bleeding, irregular menstrual cycles, and abdominal/pelvic distention or
            pain.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Treatment for prepubertal cryptorchidism is usually started between 4 and 9 y. HCG can help predict whether orchidopexy will
            be needed in the future.
         </li>
<li>When used for treatment of infertility, timing of coitus is important. Daily intercourse is encouraged from day before HCG
            is given until ovulation occurs.
         </li>
<li>Report promptly onset of abdominal pain and distension (ovarian hyperstimulation syndrome).</li>
<li>Report to physician if the following appear: axillary, facial, pubic hair; penile growth; acne; deepening of voice. Induction
            of androgen secretion by HCG may induce precocious puberty in patient treated for cryptorchidism.
         </li>
<li>Observe for signs of fluid retention. A weight chart should be maintained for a biweekly record. Report to physician if weight
            gain is associated with edema.
         </li>
<li>Report vaginal bleeding during treatment of corpus luteum deficiency; drug will be discontinued.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>